Booth No.
JHVS V-35

JAPAN ジャパン・ヘルスケアベンチャー・サミット
HEALTHCARE VENTURE
SUMMIT 2018

Company

National Institutes of Biomedical Innovation, Health and Nutrition

Presenter
Haruhiko Kamada

- Overall goal of our antibody screening project is to support and accelerate antibody drug discovery through providing unique antibody-related technologies to the developers.
- We have developed a patented technology, called "epitope-equalized antibody panel (EEAP)", which consists of a minimum number of antibodies whose epitopes are evenly distributed on a target surface.
- EEAP enabled us to discover several novel functional antibodies to CD30, showing agonistic or antagonistic function.
- We are extending the epitope-driven approach in order to design a new class of epitope-based antibody drugs.

Discovery and refinement of drug candidates



Our unique technology

Epitope-equalized antibody panel (EEAP)

= Production of the comprehensive panel of a minimum number of antibodies whose epitopes are evenly distributed over the entire accessible surface of a target



Process of Ab panel maturation





Advantage of EEAP in antibody drug discovery



	Conventional antibody panel (affinity-based selection)	Epitope-classified antibody panel (binning-based selection)	Epitope-equalized antibody panel (epitope distribution-based selection)
Total number of antibody :	High	Moderate	Low
Drug discovery prospect :	Low	Moderate	High